全体要約
提供内容別に見ると、創薬AI市場はソフトウェアとサービスに分かれますが、2022年にはサービスが最大の市場シェアを保持しました。さらに、利用ケース別では、2022年に小分子設計と最適化が最大のシェアを占めています。市場の主なプレイヤーには、NVIDIA Corporation、Exscientia、BenevolentAI、Recursionなどが含まれ、これらの企業は製品の発表や投資を通じて市場での競争力を高めています。
関連する質問
49億USD (2028年)
40.2% (2023年から2028年)
NVIDIA Corporation, Exscientia, BenevolentAI, Recursion, Insilico Medicine, Schrödinger, Inc., Microsoft Corporation, Google, Atomwise Inc., Illumina, Inc., NuMedii, Inc., XtalPi Inc., Iktos, Tempus Labs, Deep Genomics, Inc., Verge Genomics, BenchSci, Insitro, Valo Health, BPGbio, Inc., IQVIA Inc, Labcorp, Tencent Holdings Limited, Predictive Oncology, Inc., Celsius Therapeutics, CytoReason, Owkin, Inc., Cloud Pharmaceuticals, Evaxion Biotech, Standigm, BIOAGE, Envisagenics, Aria Pharmaceuticals, Inc.
薬剤発見のコストと時間を削減する必要性, 薬の特許切れ, 跨業界のコラボレーションとパートナーシップの増加
概要
「サービスセグメントは2022年に主要なシェアを占め、予測期間中に最も高い成長が期待されています。」
提供に基づいて、医薬品発見におけるAI市場はソフトウェアとサービスに二分されます。2022年にはこのセグメントが医薬品発見におけるAIサービス市場の最大の市場シェアを占め、予測期間中に最も速いCAGRで成長すると予想されています。サービスを通じてAI技術と専門知識にアクセスすることで、製薬会社が医薬品発見にAIを導入する際の障壁が減少します。これは、広範な社内AI能力を持たない小規模企業にとって特に有益であり、彼らが大きな初期投資を行うことなくAIの力を活用できるようにします。
「機械学習技術セグメントは、世界のAIによるドラッグディスカバリー市場で最大のシェアを占めました。」
技術に基づいて、医薬品発見市場は機械学習、自然言語処理（NLP）、コンテキスト対応処理、その他の技術に分かれています。機械学習セグメントは2022年に全球市場の中で最大のシェアを占め、予測期間中に最も高いCAGRで成長すると予想されています。機械学習は、人体内での潜在的な医薬品候補の挙動を予測するモデルの作成を可能にします。これにより、成功の可能性が最も高い化合物の特定が支援され、失敗した候補に関連するコストと時間の削減が実現します。機械学習は、患者データを分析して個々の薬に対する反応を予測することで、個別化医療戦略の開発にも貢献します。これにより、遺伝的、分子的、臨床的情報に基づいて治療を調整できるため、より効果的な結果が得られ、医薬品発見プロセスの加速にもつながり、このセグメントの市場成長を支える要因となっています。
「小分子設計と最適化セグメントは、2022年に市場のユースケースセグメントで最大のシェアを占めると予想されています。」
使用ケースに基づいて、医薬品発見市場におけるAIは、小分子設計と最適化、病気の理解、安全性と毒性、ワクチン設計と最適化、抗体およびその他の生物製剤の設計と最適化に分かれています。2022年には、小分子設計と最適化セグメントが医薬品発見市場において最も大きなシェアを占めていました。AIは、小分子設計と最適化において主に二つの目的で活用されています。第一に、既存の化学ライブラリをスクリーニングしたり、生成的なデ・ノボ設計を通じて、ヒット類似化合物やリード類似化合物の特定を支援します。第二に、AIは特定されたヒットを最適化し、結合親和性、毒性、合成などの望ましい特性を確保し、最終的にはより効果的で安全な医薬品候補の開発につながります。これらの要因は、医薬品発見の使用ケースに特化したAIアルゴリズムの開発と洗練に寄与しています。
「北米が2022年の医薬品発見におけるAI市場を支配する」
世界のAIによる医薬品発見市場は、北米、ヨーロッパ、APAC、その他の地域という4つの主要地域に分かれています。2022年、北米はAIによる医薬品発見の地域市場で最も大きく、最も成長の速い地域でした。北米には、多くの製薬大手やバイオテクノロジーの革新者が集まり、AIの医薬品発見における能力を積極的に探求しています。これらの業界リーダーは、AI駆動の研究開発に大規模な投資を行い、市場の成長を促進しています。北米の医薬品とヘルスケアに関する確立された規制フレームワークは、業界の基準やガイドラインに準拠しながら、AI技術の統合を促進しています。これらの要因が、北米におけるAIによる医薬品発見市場を牽引するでしょう。
供給側、需要側、主要インタビューの内訳、企業の種類、職位、地域別：
・会社タイプ別：
供給サイド別：Tier 1 (31％)、Tier 2 (28％)、Tier 3 (41％)
• 需要側によると：購買マネージャー（45％）、人工知能、機械学習、薬物発見、計算分子設計の責任者（30％）、研究科学者（25％）。
• 職種別：Cレベル（31％）、ディレクター級（25％）、その他（44％）
地域別: 北米 (45%), 欧州 (20%), アジア太平洋 (28%), 南米 (4%), 中東 & アフリカ (3%)。
この市場の主要なプレーヤーは、NVIDIA Corporation（米国）、Exscientia（英国）、BenevolentAI（英国）、Recursion（米国）、Insilico Medicine（米国）、Schrödinger, Inc.（米国）、Microsoft Corporation（米国）、Google（米国）、Atomwise Inc.（米国）、Illumina, Inc.（米国）、NuMedii, Inc.（米国）、XtalPi Inc.（米国）、Iktos（フランス）、Tempus Labs（米国）、Deep Genomics, Inc.（カナダ）、Verge Genomics（米国）、BenchSci（カナダ）、Insitro（米国）、Valo Health（米国）、BPGbio, Inc.（米国）、IQVIA Inc（米国）、Labcorp（米国）、Tencent Holdings Limited（中国）、Predictive Oncology, Inc.（米国）、Celsius Therapeutics（米国）、CytoReason（イスラエル）、Owkin, Inc.（米国）、Cloud Pharmaceuticals（米国）、Evaxion Biotech（デンマーク）、Standigm（韓国）、BIOAGE（米国）、Envisagenics（米国）、およびAria Pharmaceuticals, Inc.（米国）です。プレーヤーは、新製品の発表や強化、投資、パートナーシップ、協力、合弁事業、資金調達、買収、拡張、契約、販売契約、及びアライアンスなど、有機的及び無機的な成長戦略を採用して、提供内容を増やし、顧客の未充足なニーズに応え、収益性を高め、グローバル市場での存在感を拡大しています。
リサーチカバレッジ
この報告書は、提供、技術、治療領域、使用例、プロセス、エンドユーザー、および地域に基づいて、薬物発見におけるAI市場を調査しています。
この報告書は、市場成長に影響を与える要因（推進要因、抑制要因、機会、課題など）を分析しています。
このレポートは、利害関係者にとっての市場での機会と課題を評価し、市場のリーダーに対する競争環境の詳細を提供。
この報告書は、医薬品発見におけるAI市場全体への成長動向、展望、貢献に関連してマイクロ市場を調査しています。
レポートでは、5つの主要地域に関する市場セグメントの収益を予測しています。
レポートを購入する理由
この報告書は、確立された企業だけでなく、新規参入企業や小規模企業が市場の動向を把握するのに役立ち、それによってより大きなシェアを獲得する手助けとなります。報告書を購入する企業は、以下に挙げる5つの戦略の1つまたは組み合わせを使用することができます。
このレポートは以下のポイントに関する洞察を提供します：
AIによる医薬品発見市場の成長に影響を与える主要な要因（産業間コラボレーションとパートナーシップの増加、医薬品発見と開発コストの制御ニーズの高まり、いくつかの医薬品の特許満了）、制約（AI労働力の不足および医療ソフトウェアに関するあいまいな規制ガイドライン）、機会（バイオテクノロジー産業の成長、新興市場、人間を意識したAIシステムの開発に焦点を当てること、COVID-19パンデミックにもかかわらず医薬品および生物学的製品市場の成長）、そして課題（データセットの限られた利用可能性）。
製品開発／イノベーション：医薬品発見市場における今後の技術、研究開発活動、製品発売に関する詳細な洞察。
市場の発展：収益性の高い新興市場に関する包括的な情報。レポートでは、地域ごとの医薬品発見ソリューションにおけるさまざまな種類のAI市場を分析しています。
市場の多様化：製品、未開発地域、最近の動向、そして薬剤発見におけるAIに関する投資に関する詳細な情報。
競争評価：AIによる薬剤発見市場における主要プレーヤーの市場シェア、戦略、製品、流通ネットワーク、製造能力の詳細な評価です。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 イントロダクション 38
1.1 調査の目的 38
1.2 市場の定義 38
1.2.1 包含・除外事項 39
1.3 市場範囲 40
1.3.1 市場セグメンテーション 40
1.3.2 対象地域 41
1.3.3 対象年 41
1.3.4 通貨 42
1.4 ステークホルダー 42
1.5 変化のサマリー 43
1.5.1 リセッション時のインパクト 44
2 調査手法 45
2.1 リサーチデータ 45
2.2 二次情報 46
2.2.1 二次情報の主要データ 47
2.3 一次データ 47
2.3.1 一次情報 48
- 2.3.1.1 一次情報の主要データ 49
- 2.3.1.2 業界についての主な考察 50
2.3.2 一次インタビュー内訳 50
2.4 市場規模予測 51
2.5 市場の内訳とデータのトライアンギュレーション 58
2.6 前提 59
2.6.1 マーケットサイジングの前提 59
2.6.2 スタディ全体の前提条件 59
2.7 制約 60
2.8 リスク評価 60
2.9 リセッション時のインパクト分析 61
3 エグゼクティブサマリー 63
4 更なる考察 68
4.1 創薬AI市場におけるプレーヤーの魅力的な機会 68
4.2 創薬AI市場：地域情勢 69
4.3 創薬AI市場：地理的成長機会 69
4.4 北米の創薬AI市場：エンドユーザー・国別、2022年 70
4.5 創薬AI市場：製品別 70
4.6 創薬AI市場：技術別 71
4.7 創薬AI市場：治療分野別 71
4.8 創薬AI市場、プロセス別 72
4.9 創薬AI市場、ユースケース別 72
4.10 創薬AI市場、エンドユーザー別 73
5 市場概要 74
5.1 イントロダクション 74
5.2 市場力学 74
5.2.1 促進要因 75
5.2.2 抑制要因 78
5.2.3 市場機会 79
- 5.2.3.1 成長するバイオテクノロジー産業 79
- 5.2.3.2 エマージングマーケット 79
- 5.2.3.3 人間を意識したAIシステムの開発に注力 80
5.2.4 課題 80
- 5.2.4.1 利用可能なデータセットが限られている 80
- 5.2.4.2 必要なツールと使い勝手の欠如 80
6 業界の考察 82
6.1 主要業界動向の概要 82
6.1.1 創薬におけるAIの進化 82
6.1.2 コンピュータ支援ドラッグデザインとAI 84
6.2 サプライチェーン分析 84
6.3 ポーターのファイブフォース分析 85
6.3.1 競合・競争状況の激しさ 85
6.3.2 買い手の交渉力 85
6.3.3 サプライヤーの交渉力 86
6.3.4 代替品の脅威 86
6.3.5 新規参入の脅威 86
6.4 エコシステム/マーケットマップ 86
6.5 技術分析 87
6.5.1 ドライラボ・サービス 87
6.5.2 ウェットラボ・サービス 90
- 6.5.2.1 ケミストリーサービス 90
- 6.5.2.2 バイオロジカルサービス 91
- 6.5.2.2.1 シングルセル解析 92
6.6 価格分析 95
6.6.1 平均販売価格トレンド、地域別 95
6.6.2 指標価格分析（プロセス別 96
6.7 ビジネスモデル 96
6.8 ケーススタディ分析 99
6.8.1 ケーススタディ1：ブリストル・マイヤーズ スクイブ社とエクセンティア社 99
6.8.2 ケーススタディ2：Apeiron LLCとExscientia 100
6.9 規制分析 101
6.9.1 創薬AI市場：地域別の規制状況 101
6.9.2 規制当局、政府機関、その他組織 103
6.10 特許分析 104
6.11 主要会議・イベント（2023年第1四半期～2024年第2四半期） 108
6.12 顧客事業にインパクトのあるトレンド/ディスラプション 109
6.13 主なステークホルダーと購入基準 109
6.13.1 購買プロセスにおける主要ステークホルダー 109
6.13.2 創薬AI市場の購入基準 110
6.14 Ai由来の臨床資産 110
6.15 アンメットニーズ 120
7 創薬AIの市場、オファリング別 123
7.1 イントロダクション 124
7.2 サービス 124
7.2.1 サービス部門が最大の成長を遂げる 124
7.3 ソフトウェア 125
8 創薬AIの市場、技術別 127
8.1 イントロダクション 128
8.2 機械学習 128
8.2.1 ディープラーニング 130
- 8.2.1.1 ディープラーニング、創薬への導入が進む 130
8.2.2 教師あり学習 131
- 8.2.2.1 医薬品リポジショニングへの応用が市場を牽引 131
8.2.3 強化学習 132
8.2.4 教師なし学習 133
- 8.2.4.1 エンドユーザーの採用に影響を与える予測不可能性 133
8.2.5 その他の機械学習技術 134
8.3 自然言語処理 135
8.3.1 成長を支えるデータ識別の可能性 135
8.4 コンテキスト認識処理とコンテキスト認識コンピューティング 136
8.4.1 処理能力の向上、コネクティビティの向上が利用を後押し 136
8.5 その他の技術 137
9 創薬AI市場
9.1 イントロダクション 140
9.2 オンコロジー 140
9.3 感染症 141
9.3.1 疫病の発生がドラッグディスカバリーを後押し 141
9.4 神経学 143
9.4.1 市場を牽引する研究開発の強化が必要 143
9.5 循環器系疾患 144
9.5.1 CVD治療薬の需要増加が同分野を牽引 144
9.6 免疫学 145
9.6.1 免疫疾患の治療薬パイプラインが増加し、市場成長を後押し 145
9.7 代謝性疾患 146
9.7.1 低分子治療薬の発見におけるAIの役割が採用を促進 146
9.8 その他治療エリア 148
10 創薬AI市場、プロセス別 149
10.1 イントロダクション 150
10.2 ターゲットの特定と選択 151
10.2.1 市場成長を支える新技術の開発 151
10.3 ターゲットバリデーション 152
10.3.1 後期段階での失敗を避けるため、ターゲット検証の重要性が高まっている 152
10.4 ヒットの特定と優先順位付け 154
10.4.1 採用を推進するための大規模データ分析の必要性 154
10.5 ヒット・トゥ・リードの同定／リードの生成 155
10.5.1 Hit-to-Lead Identificationが最大のマーケットシェアを占める 155
10.6 リードの最適化 156
10.7 候補者の選定と検証 158
11 創薬AI市場、ユースケース別 160
11.1 イントロダクション 161
11.2 低分子設計と最適化 162
11.2.1 十分に検証されたAIツールの利用が市場成長を後押し 162
11.3 病気の理解 164
11.4 安全性と毒性 165
11.5 ワクチンデザインと最適化 167
11.6 抗体およびその他の生物学的製剤の設計と最適化 169
12 創薬AIの市場、エンドユーザー別 171
12.1 イントロダクション 172
12.2 製薬会社・バイオテクノロジー企業 172
12.3 受託研究機関 175
12.4 研究センター、学術・政府機関 177
12.4.1 予測期間中に最も高いCAGRを記録するセグメント 177
13 創薬AIの市場、地域別 179
13.1 イントロダクション 180
13.2 北米 180
13.2.1 北米：リセッション時のインパクト 180
13.2.2 米国 185
13.2.3 カナダ 190
13.2.4 メキシコ 194
- 13.2.4.1 市場の成長を支える政府の取り組み 194
13.3 ヨーロッパ 197
13.3.1 ヨーロッパ：リセッション時のインパクト 198
13.3.2 英国 202
- 13.3.2.1 英国が欧州で最大のシェアを占める 202
13.3.3 ドイツ 207
- 13.3.3.1 政府の支援と有利な研修制度が市場成長を促進 207
13.3.4 フランス 211
13.3.5 イタリア 214
- 13.3.5.1 市場の成長を支える強力な製薬業界 214
13.3.6 その他ヨーロッパ 218
13.4 アジア太平洋 222
13.4.1 アジア太平洋：リセッション時のインパクト 222
13.4.2 日本 226
- 13.4.2.1 日本がAPAC市場を支配 226
13.4.3 中国 230
- 13.4.3.1 成長するCMO市場と異業種コラボレーションが市場を牽引 230
13.4.4 インド 234
- 13.4.4.1 市場成長を支えるAI技術の着実な採用 234
13.4.5 その他アジア太平洋 238
13.5 南米 242
13.6 中東・アフリカ 246
14 競合情勢 251
14.1 主要企業の成功戦略 251
14.2 収益分析 256
14.3 市場シェア分析 257
14.4 企業評価マトリックス 260
14.4.1 STARS 260
14.4.2 EMERGING LEADERS 260
14.4.3 PERVASIVE PLAYERS 260
14.4.4 PARTICIPANTS 261
14.4.5 企業フットプリント 262
14.5 スタートアップ/中小企業評価マトリックス 266
14.5.1 PROGRESSIVE COMPANIES 266
14.5.2 RESPONSIVE COMPANIES 266
14.5.3 DYNAMIC COMPANIES 266
14.5.4 STARTING BLOCKS 266
14.5.5 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING 268
14.6 競合他社のシナリオと動向 271
14.6.1 製品ローンチ・改良 271
14.6.2 ディール 273
14.6.3 その他の展開 274
15 企業プロファイル 276
15.1 主要企業 276
15.1.1 NVIDIA CORPORATION 276
15.1.2 EXSCIENTIA 284
15.1.3 GOOGLE 294
15.1.4 BENEVOLENTAI 299
15.1.5 RECURSION 303
15.1.6 INSILICO MEDICINE 307
15.1.7 SCHRÖDINGER, INC 314
15.1.8 MICROSOFT CORPORATION 319
15.1.9 ATOMWISE INC 323
15.1.10 ILLUMINA, INC 325
15.1.11 NUMEDII, INC 330
15.1.12 XTALPI INC 332
15.1.13 IKTOS 335
15.1.14 TEMPUS LABS 341
15.1.15 DEEP GENOMICS, INC 345
15.1.16 VERGE GENOMICS 347
15.1.17 BENCHSCI 349
15.1.18 INSITRO 351
15.1.19 VALO HEALTH 353
15.1.20 BPGBIO, INC 356
15.2 OTHER EMERGING PLAYERS 358
15.2.1 プレディクティブ・オンコロジー社 358
15.2.2 ラボコープ 359
15.2.3 IQVIA社 360
15.2.4 テンセント・ホールディングス・リミテッド 361
15.2.5 セルシウス・セラピューティクス 362
15.2.6 サイトシーズン 363
15.2.7 株式会社オウキン 364
15.2.8 クラウド医薬品 364
15.2.9 エバクシオン・バイオテック 365
15.2.10 スタンディグム 365
15.2.11 バイオエイジ・ラボ 366
15.2.12 エンビサジェニックス 366
15.2.13 アリア・ファーマシューティカルズ 367
16 付録 368
16.1 ディスカッションガイド 368
16.2 ナレッジストア 375
16.3 カスタマイズオプション 377
16.4 関連レポート 378
16.5 執筆者の詳細 379
2023 VS.2028（百万米ドル） 65
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
Table of Contents
1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.2.1 INCLUSIONS AND EXCLUSIONS 39
1.3 MARKET SCOPE 40
1.3.1 MARKET SEGMENTATION 40
1.3.2 REGIONAL SCOPE 41
1.3.3 YEARS CONSIDERED 41
1.3.4 CURRENCY CONSIDERED 42
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 43
1.5.1 RECESSION IMPACT 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
2.2 SECONDARY SOURCES 46
2.2.1 KEY DATA FROM SECONDARY SOURCES 47
2.3 PRIMARY DATA 47
2.3.1 PRIMARY SOURCES 48
- 2.3.1.1 Key data from primary sources 49
- 2.3.1.2 Key industry insights 50
2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS 50
2.4 MARKET SIZE ESTIMATION 51
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 58
2.6 ASSUMPTIONS 59
2.6.1 MARKET SIZING ASSUMPTIONS 59
2.6.2 OVERALL STUDY ASSUMPTIONS 59
2.7 LIMITATIONS 60
2.8 RISK ASSESSMENT 60
2.9 RECESSION IMPACT ANALYSIS 61
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 68
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AI IN DRUG DISCOVERY MARKET 68
4.2 AI IN DRUG DISCOVERY MARKET: REGIONAL LANDSCAPE 69
4.3 AI IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 69
4.4 NORTH AMERICAN AI IN DRUG DISCOVERY MARKET, BY END USER & COUNTRY, 2022 70
4.5 AI IN DRUG DISCOVERY MARKET, BY OFFERING 70
4.6 AI IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 71
4.7 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 71
4.8 AI IN DRUG DISCOVERY MARKET, BY PROCESS 72
4.9 AI IN DRUG DISCOVERY MARKET, BY USE CASE 72
4.10 AI IN DRUG DISCOVERY MARKET, BY END USER 73
5 MARKET OVERVIEW 74
5.1 INTRODUCTION 74
5.2 MARKET DYNAMICS 74
5.2.1 DRIVERS 75
- 5.2.1.1 Growing cross-industry collaborations and partnerships 75
- 5.2.1.2 Growing need to reduce time and cost of drug discovery and development 77
- 5.2.1.3 Patent expiry of several drugs 77
5.2.2 RESTRAINTS 78
- 5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software 78
5.2.3 OPPORTUNITIES 79
- 5.2.3.1 Growing biotechnology industry 79
- 5.2.3.2 Emerging markets 79
- 5.2.3.3 Focus on developing human-aware AI systems 80
5.2.4 CHALLENGES 80
- 5.2.4.1 Limited availability of data sets 80
- 5.2.4.2 Lack of required tools and usability 80
6 INDUSTRY INSIGHTS 82
6.1 OVERVIEW OF KEY INDUSTRY TRENDS 82
6.1.1 EVOLUTION OF AI IN DRUG DISCOVERY 82
6.1.2 COMPUTER-AIDED DRUG DESIGN AND AI 84
6.2 SUPPLY CHAIN ANALYSIS 84
6.3 PORTER’S FIVE FORCES ANALYSIS 85
6.3.1 INTENSITY OF COMPETITIVE RIVALRY 85
6.3.2 BARGAINING POWER OF BUYERS 85
6.3.3 BARGAINING POWER OF SUPPLIERS 86
6.3.4 THREAT OF SUBSTITUTES 86
6.3.5 THREAT OF NEW ENTRANTS 86
6.4 ECOSYSTEM/MARKET MAP 86
6.5 TECHNOLOGY ANALYSIS 87
6.5.1 DRY LAB SERVICES 87
6.5.2 WET LAB SERVICES 90
- 6.5.2.1 Chemistry services 90
- 6.5.2.2 BIOLOGICAL SERVICES 91
- 6.5.2.2.1 Single-cell analysis 92
6.6 PRICING ANALYSIS 95
6.6.1 AVERAGE SELLING PRICE TRENDS, BY REGION 95
6.6.2 INDICATIVE PRICING ANALYSIS, BY PROCESS 96
6.7 BUSINESS MODELS 96
6.8 CASE STUDY ANALYSIS 99
6.8.1 CASE STUDY 1: BRISTOL MYERS SQUIBB AND EXSCIENTIA 99
6.8.2 CASE STUDY 2: APEIRON LLC AND EXSCIENTIA 100
6.9 REGULATORY ANALYSIS 101
6.9.1 AI IN DRUG DISCOVERY MARKET: REGULATORY LANDSCAPE, BY REGION 101
6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
6.10 PATENT ANALYSIS 104
6.11 KEY CONFERENCES & EVENTS (Q1 2023-Q2 2024) 108
6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 109
6.13 KEY STAKEHOLDERS & BUYING CRITERIA 109
6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 109
6.13.2 BUYING CRITERIA FOR AI IN DRUG DISCOVERY MARKET 110
6.14 AI-DERIVED CLINICAL ASSETS 110
6.15 UNMET NEEDS 120
6.15.1 UNMET NEEDS IN AI IN DRUG DISCOVERY 120
6.15.2 SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY 121
6.15.3 KEY UNMET NEEDS AND PAIN POINTS FOR AI APPLICATIONS IN SINGLE-CELL ANALYSIS FOR DRUG DISCOVERY 122
7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING 123
7.1 INTRODUCTION 124
7.2 SERVICES 124
7.2.1 SERVICES SEGMENT TO WITNESS HIGHEST GROWTH 124
7.3 SOFTWARE 125
7.3.1 BENEFITS OF SOFTWARE IN DRUG DISCOVERY AND STRONG DEMAND AMONG END USERS TO DRIVE GROWTH 125
8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 127
8.1 INTRODUCTION 128
8.2 MACHINE LEARNING 128
8.2.1 DEEP LEARNING 130
- 8.2.1.1 Deep learning to see growing adoption in drug discovery 130
8.2.2 SUPERVISED LEARNING 131
- 8.2.2.1 Applications in drug repositioning to drive market 131
8.2.3 REINFORCEMENT LEARNING 132
- 8.2.3.1 Potential for machines and software to automatically determine behavior to support adoption 132
8.2.4 UNSUPERVISED LEARNING 133
- 8.2.4.1 Unpredictability to affect end-user adoption 133
8.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 134
8.3 NATURAL LANGUAGE PROCESSING 135
8.3.1 POTENTIAL APPLICATIONS IN DATA IDENTIFICATION TO SUPPORT GROWTH 135
8.4 CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING 136
8.4.1 RISING PROCESSING POWER, IMPROVED CONNECTIVITY TO BOOST USAGE 136
8.5 OTHER TECHNOLOGIES 137
9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
9.1 INTRODUCTION 140
9.2 ONCOLOGY 140
9.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH 140
9.3 INFECTIOUS DISEASES 141
9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 141
9.4 NEUROLOGY 143
9.4.1 NEED TO BOOST DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 143
9.5 CARDIOVASCULAR DISEASES 144
9.5.1 RISING DEMAND FOR CVD DRUGS TO DRIVE SEGMENT 144
9.6 IMMUNOLOGY 145
9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH 145
9.7 METABOLIC DISEASES 146
9.7.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION 146
9.8 OTHER THERAPEUTIC AREAS 148
10 AI IN DRUG DISCOVERY MARKET, BY PROCESS 149
10.1 INTRODUCTION 150
10.2 TARGET IDENTIFICATION & SELECTION 151
10.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 151
10.3 TARGET VALIDATION 152
10.3.1 RISING EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE 152
10.4 HIT IDENTIFICATION & PRIORITIZATION 154
10.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION 154
10.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION 155
10.5.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE 155
10.6 LEAD OPTIMIZATION 156
10.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION 156
10.7 CANDIDATE SELECTION & VALIDATION 158
10.7.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES 158
11 AI IN DRUG DISCOVERY MARKET, BY USE CASE 160
11.1 INTRODUCTION 161
11.2 SMALL-MOLECULE DESIGN & OPTIMIZATION 162
11.2.1 AVAILABILITY OF WELL-VALIDATED AI TOOLS TO BOOST MARKET GROWTH 162
11.3 UNDERSTANDING DISEASE 164
11.3.1 RISING DATA MINING TO LINK TARGETS TO DISEASES AND DRUG REPURPOSING TO DRIVE MARKET 164
11.4 SAFETY & TOXICITY 165
11.4.1 TOXICOLOGY AND OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO PROPEL MARKET GROWTH 165
11.5 VACCINE DESIGN & OPTIMIZATION 167
11.5.1 GROWING ADOPTION OF AI FOR EPITOPE SELECTION, PREDICTION, AND BINDING TO AUGMENT MARKET GROWTH 167
11.6 ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION 169
11.6.1 GROWING ADOPTION OF AI FOR ANTIBODY PROPERTY PREDICTION TO DRIVE MARKET 169
12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 171
12.1 INTRODUCTION 172
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 172
12.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT TO DRIVE MARKET 172
12.3 CONTRACT RESEARCH ORGANIZATIONS 175
12.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS 175
12.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 177
12.4.1 SEGMENT TO REGISTER HIGHEST CAGR OVER FORECAST PERIOD 177
13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 179
13.1 INTRODUCTION 180
13.2 NORTH AMERICA 180
13.2.1 NORTH AMERICA: RECESSION IMPACT 180
13.2.2 US 185
- 13.2.2.1 Strong economy and trend of early adoption of technologies to drive market 185
13.2.3 CANADA 190
- 13.2.3.1 Growing research on AI technologies and emergence of new AI-based start-ups to support market growth 190
13.2.4 MEXICO 194
- 13.2.4.1 Government initiatives to support market growth 194
13.3 EUROPE 197
13.3.1 EUROPE: RECESSION IMPACT 198
13.3.2 UK 202
- 13.3.2.1 UK to hold largest share in Europe 202
13.3.3 GERMANY 207
- 13.3.3.1 Government support and favorable training programs to propel market growth 207
13.3.4 FRANCE 211
- 13.3.4.1 Strong government support and favorable strategies & initiatives to drive market 211
13.3.5 ITALY 214
- 13.3.5.1 Strong pharmaceutical industry to support market growth 214
13.3.6 REST OF EUROPE 218
13.4 ASIA PACIFIC 222
13.4.1 ASIA PACIFIC: RECESSION IMPACT 222
13.4.2 JAPAN 226
- 13.4.2.1 Japan to dominate APAC market 226
13.4.3 CHINA 230
- 13.4.3.1 Growing CMO market and cross-industry collaborations to drive market 230
13.4.4 INDIA 234
- 13.4.4.1 Steady adoption of AI technologies to support market growth 234
13.4.5 REST OF ASIA PACIFIC 238
13.5 SOUTH AMERICA 242
13.5.1 SHORTAGE OF SKILLED LABOR AND GROWING REQUIREMENTS TO DRIVE AI ADOPTION 242
13.5.2 SOUTH AMERICA: RECESSION IMPACT 243
13.6 MIDDLE EAST & AFRICA 246
13.6.1 LIMITED COMPANY PRESENCE AND LARGE SCOPE FOR GROWTH TO FAVOR AI MARKET 246
13.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 246
14 COMPETITIVE LANDSCAPE 251
14.1 KEY PLAYER STRATEGIES/RIGHT TO WIN 251
14.2 REVENUE ANALYSIS 256
14.3 MARKET SHARE ANALYSIS 257
14.4 COMPANY EVALUATION MATRIX 260
14.4.1 STARS 260
14.4.2 EMERGING LEADERS 260
14.4.3 PERVASIVE PLAYERS 260
14.4.4 PARTICIPANTS 261
14.4.5 COMPANY FOOTPRINT 262
14.5 START-UP/SME EVALUATION MATRIX 266
14.5.1 PROGRESSIVE COMPANIES 266
14.5.2 RESPONSIVE COMPANIES 266
14.5.3 DYNAMIC COMPANIES 266
14.5.4 STARTING BLOCKS 266
14.5.5 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING 268
14.6 COMPETITIVE SCENARIOS AND TRENDS 271
14.6.1 PRODUCT LAUNCHES & ENHANCEMENTS 271
14.6.2 DEALS 273
14.6.3 OTHER DEVELOPMENTS 274
15 COMPANY PROFILES 276
15.1 KEY PLAYERS 276
15.1.1 NVIDIA CORPORATION 276
15.1.2 EXSCIENTIA 284
15.1.3 GOOGLE 294
15.1.4 BENEVOLENTAI 299
15.1.5 RECURSION 303
15.1.6 INSILICO MEDICINE 307
15.1.7 SCHRÖDINGER, INC 314
15.1.8 MICROSOFT CORPORATION 319
15.1.9 ATOMWISE INC 323
15.1.10 ILLUMINA, INC 325
15.1.11 NUMEDII, INC 330
15.1.12 XTALPI INC 332
15.1.13 IKTOS 335
15.1.14 TEMPUS LABS 341
15.1.15 DEEP GENOMICS, INC 345
15.1.16 VERGE GENOMICS 347
15.1.17 BENCHSCI 349
15.1.18 INSITRO 351
15.1.19 VALO HEALTH 353
15.1.20 BPGBIO, INC 356
15.2 OTHER EMERGING PLAYERS 358
15.2.1 PREDICTIVE ONCOLOGY, INC 358
15.2.2 LABCORP 359
15.2.3 IQVIA INC 360
15.2.4 TENCENT HOLDINGS LIMITED 361
15.2.5 CELSIUS THERAPEUTICS 362
15.2.6 CYTOREASON 363
15.2.7 OWKIN, INC 364
15.2.8 CLOUD PHARMACEUTICALS 364
15.2.9 EVAXION BIOTECH 365
15.2.10 STANDIGM 365
15.2.11 BIOAGE LABS 366
15.2.12 ENVISAGENICS 366
15.2.13 ARIA PHARMACEUTICALS, INC 367
16 APPENDIX 368
16.1 DISCUSSION GUIDE 368
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 375
16.3 CUSTOMIZATION OPTIONS 377
16.4 RELATED REPORTS 378
16.5 AUTHOR DETAILS 379
2023 VS. 2028 (USD MILLION) 65
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD TABLE 2 FACTOR ANALYSIS TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET TABLE 4 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH) TABLE 5 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION) TABLE 6 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION) TABLE 7 AI IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS TABLE 8 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2021-2023) TABLE 9 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023 TABLE 10 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS TABLE 11 AI IN DRUG DISCOVERY MARKET: INDICATIVE PRICING, BY PROCESS TABLE 12 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 13 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN DRUG DISCOVERY MARKET, 2021-2023 TABLE 14 KEY AI-DERIVED CLINICAL ASSETS, BY COMPANY TABLE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 19 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 23 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 24 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 25 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 27 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 28 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 29 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 31 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 32 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 33 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 40 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 41 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 43 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 45 AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 46 AI IN DRUG DISCOVERY MARKET FOR SMALL-MOLECULE DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 47 AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASE, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 48 AI IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 49 AI IN DRUG DISCOVERY MARKET FOR VACCINE DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 50 AI IN DRUG DISCOVERY MARKET FOR ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 51 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 52 INDICATIVE LIST OF DEVELOPMENTS RELATED TO AI IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY TABLE 53 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 54 INDICATIVE LIST OF COLLABORATIONS WITH CROS TABLE 55 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 56 INDICATIVE LIST OF RESEARCH COLLABORATIONS TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2021-2028 (USD MILLION) TABLE 59 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 60 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 61 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 63 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 64 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 65 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 67 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS TABLE 68 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 69 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 70 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 71 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 2021-2028 (USD MILLION) TABLE 72 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2021-2028 (USD MILLION) TABLE 73 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 74 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 75 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 76 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 77 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 78 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 79 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 80 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 81 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 82 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 83 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 84 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 85 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 86 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 87 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 88 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 89 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 90 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 91 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 92 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 93 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 94 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 95 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 96 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 97 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS TABLE 98 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 99 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 100 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 101 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 102 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 103 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 104 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 105 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 106 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 107 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 108 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 109 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 110 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 111 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 112 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 113 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 114 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 115 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 116 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 117 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 119 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 120 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 121 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 126 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 139 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 140 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 141 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 142 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 143 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 144 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 145 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 146 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 147 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 148 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 149 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 150 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 151 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 152 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 153 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 154 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 155 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 156 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 157 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 158 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 159 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 160 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 161 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 162 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 163 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 164 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 165 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 166 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 167 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 168 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 169 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 170 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 171 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 172 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 173 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 174 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 175 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 176 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021-2028 (USD MILLION) TABLE 177 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) TABLE 178 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021-2028 (USD MILLION) TABLE 179 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION) TABLE 180 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021-2028 (USD MILLION) TABLE 181 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021-2028 (USD MILLION) TABLE 182 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021-2028 (USD MILLION) TABLE 183 OVERVIEW OF STRATEGIES ADOPTED BY KEY AI IN DRUG DISCOVERY PLAYERS, FEBRUARY 2021- MAY 2022 TABLE 184 AI IN DRUG DISCOVERY MARKET: DEGREE OF COMPETITION TABLE 185 USE CASE FOOTPRINT (24 COMPANIES) TABLE 186 PROCESS FOOTPRINT (24 COMPANIES) TABLE 187 REGION FOOTPRINT (24 COMPANIES) TABLE 188 COMPANY FOOTPRINT (24 COMPANIES) TABLE 189 AI IN DRUG DISCOVERY MARKET: DETAILED LIST OF KEY SMES/START-UPS TABLE 190 USE CASE FOOTPRINT (START-UPS/SMES) TABLE 191 PROCESS FOOTPRINT (START-UPS/SMES) TABLE 192 REGION FOOTPRINT (START-UPS/SMES) TABLE 193 COMPANY FOOTPRINT (START-UPS/SMES) TABLE 194 AI IN DRUG DISCOVERY MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, 2021-2023 TABLE 195 AI IN DRUG DISCOVERY MARKET: DEALS, 2021-2023 TABLE 196 AI IN DRUG DISCOVERY MARKET: OTHER DEVELOPMENTS, 2021-2023 TABLE 197 NVIDIA CORPORATION: COMPANY OVERVIEW TABLE 198 NVIDIA CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 199 NVIDIA CORPORATION: PRODUCT/SERVICE LAUNCHES TABLE 200 NVIDIA CORPORATION: DEALS TABLE 201 EXSCIENTIA: COMPANY OVERVIEW TABLE 202 EXSCIENTIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 203 EXSCIENTIA: PRODUCT/SERVICE LAUNCHES TABLE 204 EXSCIENTIA: DEALS TABLE 205 EXSCIENTIA: OTHER DEVELOPMENTS TABLE 206 GOOGLE: COMPANY OVERVIEW TABLE 207 GOOGLE: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 208 GOOGLE: PRODUCT/SERVICE LAUNCHES TABLE 209 GOOGLE: DEALS TABLE 210 GOOGLE: OTHER DEVELOPMENTS TABLE 211 BENEVOLENTAI: COMPANY OVERVIEW TABLE 212 BENEVOLENTAI: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 213 BENEVOLENTAI: DEALS TABLE 214 RECURSION: COMPANY OVERVIEW TABLE 215 RECURSION: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 216 RECURSION: PRODUCT/SERVICE LAUNCHES TABLE 217 RECURSION: DEALS TABLE 218 RECURSION: OTHER DEVELOPMENTS TABLE 219 INSILICO MEDICINE: COMPANY OVERVIEW TABLE 220 INSILICO MEDICINE: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 221 INSILICO MEDICINE: PRODUCT/SERVICE LAUNCHES TABLE 222 INSILICO MEDICINE: DEALS TABLE 223 INSILICO MEDICINE: OTHER DEVELOPMENTS TABLE 224 SCHRÖDINGER, INC.: COMPANY OVERVIEW TABLE 225 SCHRÖDINGER, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 226 SCHRÖDINGER, INC.: DEALS TABLE 227 SCHRÖDINGER, INC.: OTHER DEVELOPMENTS TABLE 228 MICROSOFT CORPORATION: COMPANY OVERVIEW TABLE 229 MICROSOFT CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 230 MICROSOFT CORPORATION: SERVICE LAUNCHES TABLE 231 MICROSOFT CORPORATION: DEALS TABLE 232 ATOMWISE INC.: COMPANY OVERVIEW TABLE 233 ATOMWISE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 234 ATOMWISE INC.: DEALS TABLE 235 ILLUMINA, INC.: COMPANY OVERVIEW TABLE 236 ILLUMINA, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 237 ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES TABLE 238 ILLUMINA, INC.: DEALS TABLE 239 NUMEDII, INC.: COMPANY OVERVIEW TABLE 240 NUMEDII, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 241 XTALPI INC.: COMPANY OVERVIEW TABLE 242 XTALPI INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 243 XTALPI INC.: DEALS TABLE 244 IKTOS: COMPANY OVERVIEW TABLE 245 IKTOS: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 246 IKTOS: DEALS TABLE 247 IKTOS: OTHER DEVELOPMENTS TABLE 248 TEMPUS LABS: COMPANY OVERVIEW TABLE 249 TEMPUS LABS: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 250 TEMPUS LABS: PRODUCT/SERVICE LAUNCHES TABLE 251 TEMPUS LABS: DEALS TABLE 252 TEMPUS LABS: OTHER DEVELOPMENTS TABLE 253 DEEP GENOMICS, INC.: COMPANY OVERVIEW TABLE 254 DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED TABLE 255 DEEP GENOMICS, INC.: DEALS TABLE 256 DEEP GENOMICS, INC.: OTHER DEVELOPMENTS TABLE 257 VERGE GENOMICS: COMPANY OVERVIEW TABLE 258 VERGE GENOMICS: PRODUCTS/SERVICES OFFERED TABLE 259 VERGE GENOMICS: DEALS TABLE 260 BENCHSCI: COMPANY OVERVIEW TABLE 261 BENCHSCI: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 262 BENCHSCI: PRODUCT/SERVICE LAUNCHES TABLE 263 BENCHSCI: OTHER DEVELOPMENTS TABLE 264 INSITRO: COMPANY OVERVIEW TABLE 265 INSITRO: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 266 INSITRO: OTHER DEVELOPMENTS TABLE 267 VALO HEALTH: COMPANY OVERVIEW TABLE 268 VALO HEALTH: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 269 VALO HEALTH: DEALS TABLE 270 VALO HEALTH: OTHER DEVELOPMENTS TABLE 271 BPGBIO, INC.: COMPANY OVERVIEW TABLE 272 BPGBIO, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED TABLE 273 BPGBIO, INC.: DEALS
FIGURE 1 AI IN DRUG DISCOVERY MARKET: MARKET SEGMENTATION FIGURE 2 RESEARCH DESIGN FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022-2027) FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS FIGURE 8 TOP-DOWN APPROACH FIGURE 9 DATA TRIANGULATION METHODOLOGY FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2023 VS. 2028 (USD MILLION) FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) FIGURE 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS FIGURE 14 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE FIGURE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHICAL SNAPSHOT FIGURE 17 GROWING NUMBER OF CROSS-INDUSTRY COLLABORATIONS & PARTNERSHIPS TO DRIVE MARKET FIGURE 18 NORTH AMERICA TO DOMINATE AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD FIGURE 19 US TO REGISTER HIGHEST REVENUE GROWTH FROM 2023 TO 2028 FIGURE 20 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US HELD LARGEST SHARE IN NORTH AMERICA, 2022 FIGURE 21 SERVICES TO HOLD MAJORITY MARKET SHARE IN 2028 FIGURE 22 MACHINE LEARNING TO RETAIN MARKET LEADERSHIP TILL 2028 FIGURE 23 ONCOLOGY TO DOMINATE MARKET IN 2028 FIGURE 24 HIT-TO LEAD IDENTIFICATION/LEAD GENERATION TO DOMINATE MARKET IN 2028 FIGURE 25 SMALL MOLECULE DESIGN & OPTIMIZATION TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028 FIGURE 27 AI IN DRUG DISCOVERY: MARKET DYNAMICS FIGURE 28 EVOLUTION OF AI IN DRUG DISCOVERY MARKET FIGURE 29 STRUCTURE-BASED DRUG DESIGNING: AI IN DRUG DISCOVERY MARKET FIGURE 30 AI IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS (2022) FIGURE 31 AI IN DRUG DISCOVERY MARKET ECOSYSTEM FIGURE 32 AI IN DRUG DISCOVERY MARKET: CLASSIFICATION FIGURE 33 AI IN LIFE SCIENCES: BUSINESS MODELS FIGURE 34 BENEFITS OF HYBRID BUSINESS MODELS FIGURE 35 SPECIALIZATION OF AI COMPANIES OVER TIME FIGURE 36 TOP PATENT OWNERS AND APPLICANTS FOR AI IN DRUG DISCOVERY SOLUTIONS (JANUARY 2011-OCTOBER 2023) FIGURE 37 AI IN DRUG DISCOVERY MARKET: PATENT ANALYSIS (JANUARY 2011-OCTOBER 2023) FIGURE 38 TOP APPLICANT COUNTRIES/REGIONS FOR AI IN DRUG DISCOVERY PATENTS (JANUARY 2012-JULY 2023) FIGURE 39 REVENUE SHIFT IN AI IN DRUG DISCOVERY MARKET FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN DRUG DISCOVERY MARKET FIGURE 41 KEY BUYING CRITERIA FOR END USERS FIGURE 42 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2022 FIGURE 43 SMALL-MOLECULE DESIGN & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 FIGURE 44 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT FIGURE 45 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022) FIGURE 46 REVENUE ANALYSIS OF TOP MARKET PLAYERS, 2022 FIGURE 47 AI IN DRUG DISCOVERY MARKET: MARKET SHARE ANALYSIS, 2022 FIGURE 48 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX, 2022 FIGURE 49 AI IN DRUG DISCOVERY MARKET: START-UP/SME EVALUATION MATRIX, 2022 FIGURE 50 NVIDIA CORPORATION: COMPANY SNAPSHOT, 2022 FIGURE 51 EXSCIENTIA: COMPANY SNAPSHOT (2022) FIGURE 52 GOOGLE: COMPANY SNAPSHOT (2022) FIGURE 53 BENEVOLENTAI: COMPANY SNAPSHOT (2022) FIGURE 54 RECURSION: COMPANY SNAPSHOT (2022) FIGURE 55 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2022) FIGURE 56 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2023) FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
